Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... each person,s digestive tract. Scientists believe that some of ... infections, but their role in human health is not ... role of these bacteria, a team of researchers led ... in the bacterial populations of two research subjects over ... 25 issue of the journal Genome Biology , ...
(Date:7/25/2014)... The Conferee Networking committee is pleased to ... These two-hour sessions provide a unique networking opportunity for ... discuss new techniques, or brainstorm new ideas in an ... for consideration is August 31, 2014, and instructions can ... committee will review the topics, and status notifications will ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
Breaking Biology Technology:Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... ... is a thermally stable, economical and high-performance solution for operations with both high and ... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ...
... in the September 24th issue of Nature , ... technology to explore the ancient history of India, the ... reveals that nearly all Indians carry genomic contributions from ... groups experienced periods of genetic isolation from each other ...
... , ANN ARBOR, Mich., Sept. 23 ... Research Edition version 4.2, a significant product upgrade for ... has been fully committed to supporting academic and non-profit ... features a completely redesigned user-interface, improved search and filter ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2New research reveals the ancestral populations of India and their relationships to modern groups 2New research reveals the ancestral populations of India and their relationships to modern groups 3Compendia Bioscience Announces the Release of Oncomine 4 Research Edition 2
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... sustains irreparable damage in the wake of a heart ... the cardiac muscle contains few stem cells, the tissue ... and cannot contract properly. In their search for ... exploring cardiac "patches" that could be transplanted into the ...
... The chemical is known as an "endocrine disruptor," a substance ... found in everything from plastic drink bottles to the linings ... for cash register receipts not to mention the urine ... BPA has been associated with the development of chronic diseases ...
... animal welfare concern and can cause great economic losses ... whole. A new website has been launched to help ... The website [ http://www.featherwel.org ] has been developed ... Veterinary Sciences to improve bird welfare through FeatherWel, a ...
Cached Biology News:A heart of gold 2BPA + chlorine = bad news 2New website will help farmers ensure hens maintain good feather cover 2
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... sequencing inserts cloned into M13/pUC-based plasmids, plasmids ... polymerase promoters, or lambda gt10 and gt11 ... of 0.1 µg/µl in water. The primers ... using SequiTherm™ EXCEL™ II DNA Polymerase with ...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
Biology Products: